arrow
M

María Jesús Vivancos

Universidad de Cantabria
H指数:20
被引数:1,946

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024)

HCV感染在HIV感染者或高风险者中的流行病学和危险因素(马德里,2022-2024)

2025-12-010
PRE
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

一项关于西班牙HIV感染者中长期卡博格韦(cabotegravir)和利匹韦林(rilpivirine)疗效及持久性的前瞻性评估(RELATIVITY研究)

2025-10-010
PRE
Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial

bictegravir/emtricitabine/tenofovir alafenamide对HIV护理中健康相关生活质量及经济结局的影响:BIC-NOW临床试验的子研究

2025-09-220
PRE
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023)

2002年至2023年西班牙人类免疫缺陷病毒感染者中丙型肝炎病毒感染流行趋势

2025-09-013
PRE
Low-effort HIV training in Spanish primary care: Long-term impact on testing and diagnosis

低投入的艾滋病培训在西班牙初级保健中的应用:对检测和诊断的长期影响

2025-08-300
PRE
Early Detection of Cancer and Precancerous Lesions in Persons With Human Immunodeficiency Virus (HIV) Through a Comprehensive Cancer Screening Protocol
2024-07-031
PRE
A Risk Assessment Tool for Predicting Fragility Fractures in People with HIV: Derivation and Internal Validation of the FRESIA Model

预测HIV感染者脆性骨折的风险评估工具: FRESIA模型的推导和内部验证

2023-10-012
OA
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
2023-09-193
PRE
HIV and HCV screening by non-infectious diseases physicians: can we improve testing and hidden infection rates?
2023-06-265
OAAI